These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 10780829)

  • 1. The validity of the pretreated, unilaterally MPTP-treated monkeys as a model of Parkinson's disease: a detailed behavioural analysis of the therapeutic and undesired effects of the D2 agonist quinpirole and the D1 agonist SKF 81297.
    Andringa G; Vermeulen RJ; Drukarch B; Renier WO; Stoof JC; Cools AR
    Behav Pharmacol; 1999 Mar; 10(2):163-73. PubMed ID: 10780829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The predictive validity of the drug-naive bilaterally MPTP-treated monkey as a model of Parkinson's disease: effects of L-DOPA and the D1 agonist SKF 82958.
    Andringa G; Lubbers L; Drukarch B; Stoof JC; Cools AR
    Behav Pharmacol; 1999 Mar; 10(2):175-82. PubMed ID: 10780830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential anti-parkinsonian effects of benzazepine D1 dopamine agonists with varying efficacies in the MPTP-treated common marmoset.
    Gnanalingham KK; Erol DD; Hunter AJ; Smith LA; Jenner P; Marsden CD
    Psychopharmacology (Berl); 1995 Feb; 117(3):275-86. PubMed ID: 7770603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The dopamine D1 agonist SKF 81297 and the dopamine D2 agonist LY 171555 act synergistically to stimulate motor behavior of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian rhesus monkeys.
    Vermeulen RJ; Drukarch B; Sahadat MC; Goosen C; Wolters EC; Stoof JC
    Mov Disord; 1994 Nov; 9(6):664-72. PubMed ID: 7845408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sub-chronic administration of the dopamine D(1) antagonist SKF 83959 in bilaterally MPTP-treated rhesus monkeys: stable therapeutic effects and wearing-off dyskinesia.
    Andringa G; Stoof JC; Cools AR
    Psychopharmacology (Berl); 1999 Oct; 146(3):328-34. PubMed ID: 10541734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The differential behavioural effects of benzazepine D1 dopamine agonists with varying efficacies, co-administered with quinpirole in primate and rodent models of Parkinson's disease.
    Gnanalingham KK; Hunter AJ; Jenner P; Marsden CD
    Psychopharmacology (Berl); 1995 Feb; 117(3):287-97. PubMed ID: 7770604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: an acute study in parkinsonian levodopa-primed monkeys.
    Grondin R; Bédard PJ; Britton DR; Shiosaki K
    Neurology; 1997 Aug; 49(2):421-6. PubMed ID: 9270571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential therapeutic effects of dopamine D1 and D2 agonists in MPTP-induced parkinsonian monkeys: clinical implications.
    Kuno S
    Eur Neurol; 1997; 38 Suppl 1():18-22. PubMed ID: 9276196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.
    Kanda T; Jackson MJ; Smith LA; Pearce RK; Nakamura J; Kase H; Kuwana Y; Jenner P
    Exp Neurol; 2000 Apr; 162(2):321-7. PubMed ID: 10739638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dyskinesias and tolerance induced by chronic treatment with a D1 agonist administered in pulsatile or continuous mode do not correlate with changes of putaminal D1 receptors in drug-naive MPTP monkeys.
    Goulet M; Grondin R; Blanchet PJ; Bédard PJ; Di Paolo T
    Brain Res; 1996 May; 719(1-2):129-37. PubMed ID: 8782872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The selective dopamine D1 receptor agonist, SKF 81297, stimulates motor behaviour of MPTP-lesioned monkeys.
    Vermeulen RJ; Drukarch B; Sahadat MC; Goosen C; Wolters EC; Stoof JC
    Eur J Pharmacol; 1993 Apr; 235(1):143-7. PubMed ID: 8100193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination treatment of the partial D2 agonist terguride with the D1 agonist SKF 82958 in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian cynomolgus monkeys.
    Akai T; Ozawa M; Yamaguchi M; Mizuta E; Kuno S
    J Pharmacol Exp Ther; 1995 Apr; 273(1):309-14. PubMed ID: 7714782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term treatment with low doses of the D1 antagonist NNC 756 and the D2 antagonist raclopride in monkeys previously exposed to dopamine antagonists.
    Lublin H; Gerlach J; Mørkeberg F
    Psychopharmacology (Berl); 1994 Apr; 114(3):495-504. PubMed ID: 7855208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trihexyphenidyl interactions with the dopamine D1-selective receptor agonist SKF-82958 and the D2-selective receptor agonist N-0923 in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced hemiparkinsonian monkeys.
    Domino EF; Ni L
    J Pharmacol Exp Ther; 1998 Jan; 284(1):307-11. PubMed ID: 9435192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of D1 and D2 agonists in primates withdrawn from long-term treatment with haloperidol: the potential role of dopamine D1 receptors in dyskinesia.
    Lublin H; Gerlach J; Peacock L
    Clin Neuropharmacol; 1992 Dec; 15(6):448-58. PubMed ID: 1362136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of adding the D-1 agonist CY 208-243 to chronic bromocriptine treatment of MPTP-monkeys: regional changes of brain dopamine receptors.
    Gagnon C; Gomez-Mancilla B; Markstein R; Bédard PJ; Di Paolo T
    Prog Neuropsychopharmacol Biol Psychiatry; 1995 Jul; 19(4):667-76. PubMed ID: 8588064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential regulation of striatal preproenkephalin and preprotachykinin mRNA levels in MPTP-lesioned monkeys chronically treated with dopamine D1 or D2 receptor agonists.
    Morissette M; Grondin R; Goulet M; Bédard PJ; Di Paolo T
    J Neurochem; 1999 Feb; 72(2):682-92. PubMed ID: 9930741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cannabinoid receptor agonist WIN 55,212-2 reduces D2, but not D1, dopamine receptor-mediated alleviation of akinesia in the reserpine-treated rat model of Parkinson's disease.
    Maneuf YP; Crossman AR; Brotchie JM
    Exp Neurol; 1997 Nov; 148(1):265-70. PubMed ID: 9398468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of D1 receptor stimulation in normal and MPTP monkeys.
    Bédard PJ; Boucher R
    Neurosci Lett; 1989 Sep; 104(1-2):223-8. PubMed ID: 2573015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dihydrexidine, a full D1 dopamine receptor agonist, induces rotational asymmetry in hemiparkinsonian monkeys.
    Johnson BJ; Peacock V; Schneider JS
    Pharmacol Biochem Behav; 1995 Aug; 51(4):617-22. PubMed ID: 7675833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.